

Ravi Anand, MD

Ravi Anand MD completed medical education in New Delhi (India) and New York City (US) and trained as a psychiatrist. He worked in international drug development in neurodegenerative and psychiatric disorders at Hoffmann-La Roche (Switzerland), Sandoz US, Novartis US, and Organon (Netherlands). During his career he participated in and led efforts for the development of numerous new chemical entities, e.g. for depression (e.g. moclobemide), senile dementia (aniracetam), Alzheimer's disease (rivastigmine), Parkinson's disease (safinamide), and suicide prevention (clozapine), and many others.

He served as a drug development consultant for many companies and as consultant Chief Medical Officer (CMO) for Newron Pharmaceuticals SpA. During the last 10 years, he has led efforts for the development of glutamate modulators for the treatment of treatment-resistant schizophrenia (TRS).